Pharsight

Drugs that contain Ganaxolone

1. Ztalmy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9056116 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(2 years from now)

US9029355 MARINUS Solid ganaxolone compositions and methods for the making and use thereof
Nov, 2026

(2 years from now)

US8618087 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(2 years from now)

US8367651 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(2 years from now)

US7858609 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(2 years from now)

US8022054 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(2 years from now)

US8318714 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(2 years from now)

US10603308 MARINUS Methods and compositions for treatment of epileptic disorders
Aug, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 01, 2027
Orphan Drug Exclusivity(ODE-395) Jun 01, 2029

NCE-1 date: 01 June, 2026

Market Authorisation Date: 01 June, 2022

Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older

Dosage: SUSPENSION;ORAL

More Information on Dosage

ZTALMY family patents

Family Patents